MxA mRNA expression as a biomarker of interferon beta response in multiple sclerosis patients

Elisabet Matas; Laura Bau; María Martínez-Iniesta; Lucía Romero-Pinel; M Alba Mañé-Martínez; Álvaro Cobo-Calvo; Sergio Martínez-Yélamos

doi:10.1016/j.jneuroim.2015.12.015

MxA mRNA expression as a biomarker of interferon beta response in multiple sclerosis patients

J Neuroimmunol. 2016 Feb 15:291:73-7. doi: 10.1016/j.jneuroim.2015.12.015. Epub 2015 Dec 30.

Authors

Elisabet Matas¹, Laura Bau², María Martínez-Iniesta³, Lucía Romero-Pinel⁴, M Alba Mañé-Martínez⁵, Álvaro Cobo-Calvo⁶, Sergio Martínez-Yélamos⁷

Affiliations

¹ Multiple Sclerosis Unit, Department of Neurology, Hospital Universitari de Bellvitge-IDIBELL, Edifici Tècnic-Quirúrgic, Planta 1, mòdul E, Feixa Llarga s/n, L'Hospitalet de Llobregat 08907, Spain. Electronic address: ematas@bellvitgehospital.cat.
² Multiple Sclerosis Unit, Department of Neurology, Hospital Universitari de Bellvitge-IDIBELL, Edifici Tècnic-Quirúrgic, Planta 1, mòdul E, Feixa Llarga s/n, L'Hospitalet de Llobregat 08907, Spain. Electronic address: lbau@bellvitgehospital.cat.
³ Translational Research Laboratory, Institut Català d'Oncologia-IDIBELL, Gran via s/n, L'Hospitalet de Llobregat 08907, Spain. Electronic address: mmi@iconcologia.net.
⁴ Multiple Sclerosis Unit, Department of Neurology, Hospital Universitari de Bellvitge-IDIBELL, Edifici Tècnic-Quirúrgic, Planta 1, mòdul E, Feixa Llarga s/n, L'Hospitalet de Llobregat 08907, Spain. Electronic address: luciaromero@bellvitgehospital.cat.
⁵ Multiple Sclerosis Unit, Department of Neurology, Hospital Universitari de Bellvitge-IDIBELL, Edifici Tècnic-Quirúrgic, Planta 1, mòdul E, Feixa Llarga s/n, L'Hospitalet de Llobregat 08907, Spain; Department of Neurology, Joan XXIII University Hospital, Universitat Rovira i Virgili, Dr. Mallafrè Guasch, 4, Tarragona 43005, Spain. Electronic address: amane.hj23.ics@gencat.cat.
⁶ Department of Neurology, Hospital del Mar Medical Research Institute, Dr. Aiguader, 88, Barcelona 08003, Spain. Electronic address: acobo@imim.es.
⁷ Multiple Sclerosis Unit, Department of Neurology, Hospital Universitari de Bellvitge-IDIBELL, Edifici Tècnic-Quirúrgic, Planta 1, mòdul E, Feixa Llarga s/n, L'Hospitalet de Llobregat 08907, Spain. Electronic address: smartinezy@bellvitgehospital.cat.

PMID: 26857498
DOI: 10.1016/j.jneuroim.2015.12.015

Abstract

Myxovirus resistance protein A (MxA) is a molecule induced after interferon-β injection. The aim of this study was to investigate whether MxA determination one year after starting interferon-β can predict treatment response in multiple sclerosis patients. MxA mRNA expression was evaluated in blood samples obtained at baseline and at month 12. Clinical variables were prospectively recorded. A threshold of 5 was defined to establish MxA induction. On survival analysis, time to the next relapse and to EDSS progression were significantly longer in patients showing MxA induction, suggesting that MxA induction after one year may be useful to identify interferon-β responders.

Keywords: Biomarker; Interferon-beta; Multiple sclerosis; MxA; Treatment response.

Publication types

Observational Study
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / genetics*
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / metabolism
Biomarkers / blood
Cohort Studies
Disability Evaluation
Female
Gene Expression Regulation / drug effects*
Humans
Immunologic Factors / therapeutic use*
Interferon-beta / therapeutic use*
Male
Middle Aged
Multiple Sclerosis / drug therapy*
Multiple Sclerosis / metabolism
Multiple Sclerosis / mortality
Prospective Studies
RNA, Messenger / metabolism*
Statistics, Nonparametric
Survival Analysis

Substances

Basic Helix-Loop-Helix Leucine Zipper Transcription Factors
Biomarkers
Immunologic Factors
MAX protein, human
RNA, Messenger
Interferon-beta